Compare SY & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SY | NGNE |
|---|---|---|
| Founded | 2013 | 2003 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 289.0M | 327.8M |
| IPO Year | 2019 | N/A |
| Metric | SY | NGNE |
|---|---|---|
| Price | $2.92 | $20.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $5.50 | ★ $38.50 |
| AVG Volume (30 Days) | ★ 962.2K | 211.4K |
| Earning Date | 11-17-2025 | 11-13-2025 |
| Dividend Yield | ★ 0.86% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $201,132,009.00 | N/A |
| Revenue This Year | $5.27 | N/A |
| Revenue Next Year | $51.30 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.67 | $6.88 |
| 52 Week High | $6.28 | $37.27 |
| Indicator | SY | NGNE |
|---|---|---|
| Relative Strength Index (RSI) | 41.24 | 41.96 |
| Support Level | $2.79 | $19.65 |
| Resistance Level | $3.33 | $23.00 |
| Average True Range (ATR) | 0.18 | 1.47 |
| MACD | 0.01 | 0.26 |
| Stochastic Oscillator | 23.15 | 33.15 |
So-Young International Inc is an online destination for discovering, evaluating, and reserving medical aesthetic services in China. Its business model comprises four integrated components: professional content and its distribution through social media networks and its targeted media platforms in China, a social community characterized by signature user-generated content, Online reservation services for a medical aesthetic treatment, and the research, development, production, sales and agency of laser and other optoelectronic medical beauty equipment. It generates revenue from information services fees and reservation services fees from medical aesthetic service providers.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.